From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article.

Original languageEnglish
Pages (from-to)67-77
Number of pages11
JournalImmunotherapy
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2021

Keywords

  • atezolizumab
  • checkpoint inhibitors
  • durvalumab
  • immunotherapy
  • nivolumab
  • PD-1
  • PD-L1
  • urothelial cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this